Lateral flow tests, also known as immunochromatographic strip (ICS) tests, are point of care tests that reduce the time spent waiting for test results from hours to minutes, require less training for operators, and reduce the cost of both device development and care. This report, Lateral Flow Technology and the Future of Point of Care Testing, 2nd Edition, takes an in depth look at the market, technologies, and trends in lateral flow point-of-care testing, looking at both self-testing by patients and at point-of-care testing by healthcare professionals.
Lateral flow (LF) devices and tests have been a popular platform for rapid immunoassays since their introduction in the mid-1980s, and since our last look at the market there has been continued interest and innovations. This report profiles over a hundred companies that currently market lateral flow tests. Many of these companies, plus more than ten additional companies, are developing innovations in lateral flow-based devices. Companies profiled in this report use lateral flow technology to develop and market a wide range of rapid tests for market segments of in vitro diagnostic (IVD) tests that can be performed in centralized laboratories.
Every critical aspect of the lateral flow test market is addressed, including the following key topics:
This report provides a realistic assessment acknowledging the reality of payors’ emphasis on cost/benefit analysis for new technologies. Current sales and predictions for 2017 sales are provided for the diabetes, oncology, cardiac marker, pregnancy and other LF test markets.
Kalorama’s unique and thorough research process provides an exhaustive analysis of this evolving market. Information was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals.
For the purpose of this study, Kalorama Information conducted telephone and email interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with device company representatives included marketing directors, division managers, and product development representatives.
The report offers a quantitative assessment of specific markets, worldwide, in U.S. dollars for 2012 to 2017.
Related Reports:The Market and Potential for Molecular Point of Care Diagnostics
Feb 5, 2014 - KLI5201690 - $3,995.00
IVD in Singapore and Malaysia
Jan 1, 2014 - KLI5177833 - $1,995.00
The World Market for Hematology
Nov 22, 2013 - KLI5156915 - $3,995.00
Retail Clinics: Consumer Attitudes Results of the 2013 Kalorama Survey
Mar 22, 2013 - KLI5007914 - $995.00
The World Market for Point of Care (POC) Diagnostics
Dec 6, 2012 - KLI4891643 - $4,200.00
Retail Clinics 2012: Growth of Stores, Consumer Opinion Surveys, Winning Competitors, Supplier Sales of Products to Clinics, Clinic Sales Forecasts and Trends
Nov 15, 2012 - KLI4911928 - $2,500.00
Cell Phone-Enabled Diagnostics: mHealth Applications in IVD
Aug 15, 2012 - KLI4862659 - $995.00
The Global Market for Medical Devices, 3rd. Edition
May 2, 2012 - KLI3873247 - $1,500.00
Point of Care Diagnostics for Emerging Infectious Disease Threats (Dengue Fever, HIV, HPV, STDs, Chagas, TB, and Other IDs): Market Analysis and Technical Considerations
Oct 1, 2011 - KLI6429399 - $2,995.00
Retail Clinics 2011: Growth of Stores, Best Venues, Winning Competitors, Supplier Sales of Products to Clinics, Clinic Sales Forecasts and Trends
May 1, 2011 - KLI6083611 - $2,995.00
Questions?Contact a research specialist >
Most Popular ResearchThe Worldwide Market for In Vitro Diagnostic (IVD) Tests, 8th Edition Results of The 2012 Kalorama IVD Procedure Count: White Paper The World Market for Point of Care (POC) Diagnostics White Paper: Animal Diagnostics: "Sister Market" to IVD? World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas) Why Epigenomics May Be a Game-Changer in Diagnostics and Pharmaceuticals